Cargando…

Postmarket Clinical Evidence for High-Risk Therapeutic Medical Devices Receiving Food and Drug Administration Premarket Approval in 2010 and 2011

This cross-sectional study provides a 5-year update on the status and availability of postmarket evidence for high-risk medical devices that received FDA premarket approval in 2010 and 2011.

Detalles Bibliográficos
Autores principales:	Rathi, Vinay K., Krumholz, Harlan M., Masoudi, Frederick A., Ross, Joseph S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455850/ https://www.ncbi.nlm.nih.gov/pubmed/32857145 http://dx.doi.org/10.1001/jamanetworkopen.2020.14496

Ejemplares similares

Market competition among manufacturers of novel high-risk therapeutic devices receiving FDA premarket approval between 2001 and 2018
por: Rathi, Vinay K, et al.
Publicado: (2023)

Overview of the Premarketing and Postmarketing Requirements for Drugs Granted Japanese Conditional Marketing Approval
por: Matsushita, Shunsuke, et al.
Publicado: (2021)

Quantification of US Food and Drug Administration Premarket Approval Statements for High-Risk Medical Devices With Pediatric Age Indications
por: Lee, Samuel J., et al.
Publicado: (2021)

Risk of Recall Among Medical Devices Undergoing US Food and Drug Administration 510(k) Clearance and Premarket Approval, 2008-2017
por: Dubin, Jonathan R., et al.
Publicado: (2021)

Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics
por: Varma, Tanvee, et al.
Publicado: (2021)

Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U.S. Food and Drug Administration approvals
por: Downing, Nicholas S., et al.
Publicado: (2016)

Time Series Analysis of the Effectiveness and Safety of Capsule Endoscopy between the Premarketing and Postmarketing Settings: A Meta-Analysis
por: Iijima, Kazuo, et al.
Publicado: (2016)

Characteristics of Postmarketing Studies for Vaccines Approved by the US Food and Drug Administration, 2006-2020
por: Moneer, Osman, et al.
Publicado: (2021)

Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
por: Wallach, Joshua D., et al.
Publicado: (2019)

Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments
por: Skydel, Joshua J., et al.
Publicado: (2019)

Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports
por: Chang, Lee, et al.
Publicado: (2015)

Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017
por: Zhang, Audrey D., et al.
Publicado: (2020)

Left to Their Own Devices: Breakdowns in United States Medical Device Premarket Review
por: Hines, Jonas Zajac, et al.
Publicado: (2010)

Premarket Approval Through the 510(k) Process: Lessons from the Translation Process of Magnetic Resonance Elastography
por: Aponte Ortiz, Jaime A., et al.
Publicado: (2018)

Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study
por: Zeitoun, Jean-David, et al.
Publicado: (2017)

Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis
Publicado: (2018)

Association of expedited review programmes with postmarketing safety events of new drugs approved by the US food and drug administration between 2007 and 2017
por: Zhu, Xingyue, et al.
Publicado: (2022)

Cardiovascular Safety Profile of Dapoxetine during the Premarketing Evaluation
por: Kowey, Peter R., et al.
Publicado: (2012)

Premarket Safety and Efficacy Studies for ADHD Medications in Children
por: Bourgeois, Florence T., et al.
Publicado: (2014)

Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021
por: Gupta, Ravi, et al.
Publicado: (2022)

Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015
por: MacGregor, Andrea, et al.
Publicado: (2020)

Demographic Characteristics of Participants in Trials Essential to US Food and Drug Administration Vaccine Approvals, 2010–2020
por: Zhang, Audrey D., et al.
Publicado: (2021)

Assessing Visual Outcomes: A Comparative Study of US-FDA Premarket Approval Data for Multifocal and EDOF Lens Implants in Cataract Surgery
por: Moshirfar, Majid, et al.
Publicado: (2023)

Recent progress to shorten premarket evaluation and improve patient access to medical devices by the Pharmaceuticals and Medical Devices Agency of Japan
por: Handa, Nobuhiro, et al.
Publicado: (2019)

Risk for Postmarket Black Box Warnings in FDA-Approved Monoclonal Antibodies
por: Hagan, John B., et al.
Publicado: (2021)

A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities
por: Lu, Dan, et al.
Publicado: (2016)

Changes in ST segment elevation myocardial infarction hospitalisations in China from 2011 to 2015
por: Zhou, Tianna, et al.
Publicado: (2021)

EU postmarket surveillance plans for medical devices
por: Pane, Josep, et al.
Publicado: (2019)

Premarket evaluation of medical devices: a cross-sectional analysis of clinical studies submitted to a German ethics committee
por: Sauerland, Stefan, et al.
Publicado: (2019)

National Trends in Recurrent AMI Hospitalizations 1 Year After Acute Myocardial Infarction in Medicare Beneficiaries: 1999–2010
por: Chaudhry, Sarwat I., et al.
Publicado: (2014)

Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
por: Lammers, Austin, et al.
Publicado: (2017)

Trends in Early Aspirin Use Among Patients With Acute Myocardial Infarction in China, 2001–2011: The China PEACE‐Retrospective AMI Study
por: Gao, Yan, et al.
Publicado: (2014)

Improving the Postmarket Surveillance of Total Joint Arthroplasty Devices
por: Mahomed, Nizar N, et al.
Publicado: (2008)

Postmarket Modifications of High-risk Plastic Surgery Devices
por: Olaiya, Oluwatobi R., et al.
Publicado: (2020)

Current development in medical devices postmarket surveillance in Taiwan
por: Lan, Cheng-Wen, et al.
Publicado: (2014)

Exploratory Analysis of Associations Between Postmarketing Safety Events and Approved Doses of New Drugs in Japan
por: Okubo, TK, et al.
Publicado: (2017)

Postmarket Safety Surveillance of Delayed Complications for Recent FDA-Approved Hyaluronic Acid Dermal Fillers
por: Cohen, Joel L., et al.
Publicado: (2022)

Patterns of Use of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Among Patients With Acute Myocardial Infarction in China From 2001 to 2011: China PEACE‐Retrospective AMI Study
por: Liu, Jiamin, et al.
Publicado: (2015)

Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration
por: Jiao, Kuo, et al.
Publicado: (2019)

Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review
por: Pease, Alison M, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_f6m3cqiu5flr03d92vak38muri